Kinase inhibitors: look beyond the label on the bottle

Abstract

The majority of scientists working in the field of cancer experimental therapeutics recognize that many drugs that claim to be “specific” for one target enzyme in fact regulate to varying degrees the activities of other additional protein targets. Some of these targets are known and are recognized as being an essential component of a drug’s biology. However, many other targets fall into the category of “unknown unknowns”. Thus, the collective therapeutic outcome for almost all clinically relevant drugs is reliant on both the claimed primary and secondary “on” targets as well as some of the unexpected unknown “off” targets. This review discusses the biology of several FDA approved cancer therapeutic drugs whose initial reported targets only represented the tip-of-the-iceberg in terms of how each agent acted as an anti-tumor drug. The review also discusses a putative thorough pre-visualization methodology for drug-based research, prior to executing any wet work. These approaches should be performed in an agnostic fashion and be based in part on the clinically safe drug’s C max and its area under the curve in a patient. Based on tumor heterogeneity, considerations of how to approach developmental therapeutics in the age of “personalized medicine” are also discussed.

Keywords

Autophagy / histone deacetylase / chaperone / cancer

References

[1] Anderson NG,Marsden LA,Roberts TM.Raf-1 is a potential substrate for mitogen-activated protein kinase in vivo..Biochem J1991;277:573-6 PMCID:PMC1151274

[2] Morrison DK,Rapp U.Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity..Proc Natl Acad Sci U S A1988;85:8855-9 PMCID:PMC282605

[3] Dent P,Haystead TA,Roberts TM.Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro..Science1992;257:1404-7

[4] Kyriakis JM,Zhang XF,Brautigan DL.Raf-1 activates MAP kinase-kinase..Nature1992;358:417-21

[5] L’Allemain G,Weber MJ.Defective regulation of mitogen-activated protein kinase activity in a 3T3 cell variant mitogenically nonresponsive to tetradecanoyl phorbol acetate..Mol Cell Biol1991;11:1002-8 PMCID:PMC359767

[6] Leevers SJ.Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein..EMBO J1992;11:569-74 PMCID:PMC556488

[7] Dudley DT,Decker SJ,Saltiel AR.A synthetic inhibitor of the mitogen-activated protein kinase cascade..Proc Natl Acad Sci U S A1995;92:7686-9 PMCID:PMC41210

[8] Alessi DR,Cohen P,Saltiel AR.PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo..J Biol Chem1995;270:27489-94

[9] Pan BT,Brott B.The 96 kDa protein kinase activated by oncogenic Ras in Xenopus egg extracts is also activated by constitutively active Mek: activation requires serine/threonine phosphorylation..Oncogene1997;14:1653-60

[10] Börsch-Haubold AG,Watson SP.Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase..J Biol Chem1998;273:28766-72

[11] Adderley SR.Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2..J Biol Chem1999;274:5038-46

[12] Suzaki Y,Kagami S,Taketani Y.Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults..J Biol Chem2002;277:9614-21

[13] Favata MF,Manos EJ,Stradley DA.Identification of a novel inhibitor of mitogen-activated protein kinase kinase..J Biol Chem1998;273:18623-32

[14] Duncia JV,Higley CA,Wityak J.MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products..Bioorg Med Chem Lett1998;8:2839-44

[15] Heinzerling L,Fluck M,Heller-Schenck D.Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management..ESMO Open2019;4:e000491 PMCID:PMC6555610

[16] Steeb T,Ruzicka T,Berking C.How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma..Eur J Cancer2018;103:41-51

[17] Hotte SJ.BAY 43-9006: early clinical data in patients with advanced solid malignancies..Curr Pharm Des2002;8:2249-53

[18] Wilhelm S.BAY 43-9006: preclinical data..Curr Pharm Des2002;8:2255-7

[19] Hilger RA,Hedley D,Bauer RJ.ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006..Int J Clin Pharmacol Ther2002;40:567-8

[20] Rahmani M,Bauer C,Grant S.Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation..J Biol Chem2005;280:35217-27

[21] Panka DJ,Atkins MB.The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells..Cancer Res2006;66:1611-9

[22] Schöffski P,Clement P,Prenen H.Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review..Ann Oncol2006;17:1185-96

[23] Strumberg D.Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment..Drugs Today (Barc)2005;41:773-84

[24] Carlomagno F,Guida T,Troncone G.BAY 43-9006 inhibition of oncogenic RET mutants..J Natl Cancer Inst2006;98:326-34

[25] Lierman E,Stover EH,Van Miegroet H.Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant..Blood2006;108:1374-6 PMCID:PMC1895882

[26] Rahmani M,Crabtree TR,Nguyen TK.The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress..Mol Cell Biol2007;27:5499-513 PMCID:PMC1952105

[27] Holz MS,Renné C,Spieker T.Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines..Mol Cancer Ther2013;12:173-83

[28] Martin AP,Mitchell C,Rahmani M.BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing..Mol Pharmacol2009;76:327-41 PMCID:PMC2713125

[29] Park MA,Häussinger D,Ogretmen B.Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells..Mol Cancer Ther2010;9:2220-31 PMCID:PMC2933415

[30] Bareford MD,Yacoub A,Tang Y.Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells..Cancer Res2011;71:4955-67 PMCID:PMC3210312

[31] Zhu J,Tseng PH,Fowble J.From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors..Cancer Res2004;64:4309-18

[32] Carón RW,Li M,Mitchell C.Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival..Mol Cancer Ther2005;4:257-70

[33] Carón RW,Zhu X,Han SI.H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent..Mol Cancer Ther2005;4:243-55

[34] Bertolotti A,Hendershot LM,Ron D.Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response..Nat Cell Biol2000;2:326-32

[35] Harding HP,Zhang Y,Wek R.Regulated translation initiation controls stress-induced gene expression in mammalian cells..Mol Cell2000;6:1099-108

[36] Lee AS.The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress..Methods2005;35:373-81

[37] Booth L,Hamed HA,Ogretmen B.OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing..Cancer Biol Ther2012;13:224-36 PMCID:PMC3336069

[38] Booth L,Albers T,Tavallai M.Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function..Oncotarget2016;7:12975-96 PMCID:PMC4914336

[39] Booth L,Cash DR,Jean S.GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease..J Cell Physiol2015;230:1661-76 PMCID:PMC4402027

[40] Booth L,Tavallai M,Chuckalovcak J.OSU-03012 and viagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood-brain barrier: implications for anti-cancer therapies..J Cell Physiol2015;230:1982-98 PMCID:PMC4835175

[41] Earl PL,Doms RW.Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein..J Virol1991;65:2047-55 PMCID:PMC240054

[42] Roberts JL,Nourbakhsh A,Cruz-Luna T.GRP78/Dna K is a target for nexavar/stivarga/votrient in the treatment of human malignancies, viral infections and bacterial diseases..J Cell Physiol2015;230:2552-78 PMCID:PMC4843173

[43] Booth L,Ecroyd H,Bavari S.AR-12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication..J Cell Physiol2016;231:2286-302 PMCID:PMC6327852

[44] Taylor EC,Shih C,Grindey GB.A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase..J Med Chem1992;35:4450-4

[45] Racanelli AC,Heyer CL.Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition..Cancer Res2009;69:5467-74 PMCID:PMC2706929

[46] Rothbart SB,Moran RG.Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas..Cancer Res2010;70:10299-309 PMCID:PMC3059241

[47] Tripathi DN,Trudel LJ,Slack RS.Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1..Proc Natl Acad Sci U S A2013;110:E2950-7 PMCID:PMC3740898

[48] Corona Velazquez AF.So many roads: the multifaceted regulation of autophagy induction..Mol Cell Biol2018;38:e00303-18 PMCID:PMC6189458

[49] Yu C,Meng XW,Carter CA.The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006..Oncogene2005;24:6861-9

[50] Zheng W,Yin D,Liu M.ATG5 and ATG7 induced autophagy interplays with UPR via PERK signaling..Cell Commun Signal2019;17:42 PMCID:PMC6503447

[51] Simmons JK,Gamache BJ,Patel J.Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation..Mol Cancer Ther2017;16:2008-21 PMCID:PMC5587368

[52] Dent P,Poklepovic A.Signaling alterations caused by drugs and autophagy..Cell Signal2019;64:109416

[53] Tao Z,Shen K,Zeng H.Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 prospective clinical trials..Clin Drug Investig2019;39:27-43

[54] Roskoski R Jr.Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers..Pharmacol Res2019;139:395-411

[55] Tagliamento M,Rijavec E,Biello F.Afatinib and Erlotinib in the treatment of squamous-cell lung cancer..Expert Opin Pharmacother2018;19:2055-62

[56] Tavallai M,Roberts JL,Dent P.Rationally repurposing ruxolitinib [Jakafi (®)] as a solid tumor therapeutic..Front Oncol2016;13;6:142 PMCID:PMC4904019

[57] Booth L,Tavallai M,Leon D.The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling..Oncotarget2016;7:19620-30 PMCID:PMC4991406

[58] Booth L,Poklepovic A,Cutler RE.HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo..Oncotarget2017;8:90262-77 PMCID:PMC5685747

[59] Booth L,Poklepovic A.NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells..Oncol Signal2018;1:19-30 PMCID:PMC6366836

[60] Davis MI,Herrgard S,Wodicka LM.Comprehensive analysis of kinase inhibitor selectivity..Nat Biotechnol2011;29:1046-51

[61] Klaeger S,Wilhelm M,Vick B.The target landscape of clinical kinase drugs..Science2017;358:eaan4368 PMCID:PMC6542668

[62] Schuster SC,Alex LA,Simon MI.Assembly and function of a quaternary signal transduction complex monitored by surface plasmon resonance..Nature1993;365:343-7

[63] Booth L,Sander C,Kirkwood JM.Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells..Cancer Biol Ther2019;20:700-10 PMCID:PMC6606002

[64] Booth L,Poklepovic A,Sander C.The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1/ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib..Cancer Biol Ther2018;19:132-7 PMCID:PMC5790370

[65] Booth L,Rais R,Diala I.Neratinib augments the lethality of [regorafenib + sildenafil]..J Cell Physiol2019;234:4874-87 PMCID:PMC6322207

[66] Cho KJ,Prakash P,van der Hoeven D.AMPK and endothelial nitric oxide synthase signaling regulates K-Ras plasma membrane interactions via cyclic GMP-dependent protein kinase 2..Mol Cell Biol2016;36:3086-99 PMCID:PMC5126295

[67] Waters AM,Vaseva AV,Strathern LA.Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies..Sci Signal2017;10:eaao3332 PMCID:PMC5812265

[68] Dent P,Roberts JL,Poklepovic A.Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells..Oncogene2019;38:5890-904

[69] Hobert ME,Carlin CR.Regulation of EGF signaling by cell polarity in MDCK kidney epithelial cells..J Cell Physiol1999;181:330-41

[70] Thompson BJ.MST kinases in development and disease..J Cell Biol2015;210:871-82 PMCID:PMC4576864

[71] Chen S,Xu S,Zhang J.Mammalian sterile20-like kinases: signalings and roles in central nervous system..Aging Dis2018;9:537-52 PMCID:PMC5988607

[72] Wang OH,Guo M,Deng D.Prognostic and functional significance of MAP4K5 in pancreatic cancer..PLoS One2016;11:e0152300 PMCID:PMC4811546

[73] Meng Z,Mottier-Pavie V,Hansen CG.MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway..Nat Commun2015;6:8357 PMCID:PMC4600732

[74] Hsu CL,Gordon KL,Shen WC.MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB..Nat Commun2018;9:942 PMCID:PMC5838220

[75] Booth L,Tavallai M,Stringer DK.[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling..Oncotarget2016;7:23608-32 PMCID:PMC5029651

[76] Booth L,Roberts JL,Poklepovic A.Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo..Oncotarget2016;7:40398-417 PMCID:PMC5130016

[77] Sridhar SS,Siu LL.Raf kinase as a target for anticancer therapeutics..Mol Cancer Ther2005;4:677-85

[78] Strumberg D,Hilger RA,Korfee S.Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors..J Clin Oncol2005;23:965-72

[79] Tavallai M,Roberts JL,Chuckalovcak J.Nexavar/Stivarga and viagra interact to kill tumor cells..J Cell Physiol2015;230:2281-98 PMCID:PMC4835179

[80] Woyach JA,Liu TM,Zapatka M.Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib..N Engl J Med2014;370:2286-94 PMCID:PMC4144824

[81] Yamaguchi F,Wakabayashi A.Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: a case report and literature review..Mol Clin Oncol2019;11:127-31 PMCID:PMC6604406

[82] Le X,Negrao MV,Robichaux J.Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC..Clin Cancer Res2018;24:6195-203 PMCID:PMC6295279